Tout­ing pro­grams from No­var­tis, Laek­na bags $100M in Hong Kong IPO while Mer­ck-part­nered Kelun seeks up to $208M

A pair of Chi­nese biotechs with Big Phar­ma ties is bring­ing some fresh IPO ac­tiv­i­ty to the biotech cor­ner of Hong Kong’s stock ex­change af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.